{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:43:28Z","timestamp":1777869808375,"version":"3.51.4"},"reference-count":76,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cancer survivors face a high burden of comorbidities which negatively influence long-term outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may augment these outcomes, but their role in this population remains understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a literature review of randomized controlled trials, observational studies, retrospective cohort studies, pre-clinical trials, and reviews related to GLP-1 RAs and cancer survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We first delineate the GLP-1 RA mechanisms of action in glycemic control, inflammation, cardiovascular protection, neuroprotection, nephroprotection, and cancer proliferation. Then, we highlight the potential clinical benefits that these drugs could have in cancer survivors based on available studies, including metabolism, cardiovascular risk, lymphedema and mortality. Finally, we address ongoing safety concerns for GLP-1 RAs, particularly focusing on their potential use in cancer survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Given the limited evidence to date, further research is needed to evaluate the long-term benefits and safety of GLP-1 RA use in cancer survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/postmj\/qgag044","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:43:42Z","timestamp":1774442622000},"source":"Crossref","is-referenced-by-count":0,"title":["The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review"],"prefix":"10.1093","author":[{"given":"George","family":"Hatzis","sequence":"first","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School , 55 Lake Avenue North, Worcester, MA, 01655 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"McKennitt","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School , 55 Lake Avenue North, Worcester, MA, 01655 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben S","family":"Gerber","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School , 55 Lake Avenue North, Worcester, MA, 01655 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryann M","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Medicine, UMass Memorial Medical Center , 55 Lake Avenue North, Worcester, MA, 01655 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-0950","authenticated-orcid":false,"given":"Jung Ae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School , 55 Lake Avenue North, Worcester, MA, 01655 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043010445971300_ref1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2026043010445971300_ref2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cncr.33981","article-title":"Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002-2018","volume":"128","author":"Jiang","year":"2022","journal-title":"Cancer."},{"key":"2026043010445971300_ref3","doi-asserted-by":"publisher","first-page":"e2433132","DOI":"10.1001\/jamanetworkopen.2024.33132","article-title":"Excess body weight and the risk of second primary cancers among cancer survivors","volume":"7","author":"Bodelon","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026043010445971300_ref4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nm.2428","article-title":"A step toward slaying the hydra of second cancers","volume":"17","author":"Morton","year":"2011","journal-title":"Nat Med"},{"key":"2026043010445971300_ref5","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1634\/theoncologist.2011-0214","article-title":"Second malignancies among elderly survivors of cancer","volume":"16","author":"VanderWalde","year":"2011","journal-title":"Oncologist"},{"key":"2026043010445971300_ref6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JOP.2015.009449","article-title":"ReCAP: ASCO Core curriculum for cancer survivorship education","volume":"12","author":"Shapiro","year":"2016","journal-title":"J Oncol Pract"},{"key":"2026043010445971300_ref7","doi-asserted-by":"publisher","first-page":"1457363","DOI":"10.3389\/fphar.2024.1457363","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)","volume":"15","author":"Brown","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026043010445971300_ref8","doi-asserted-by":"publisher","first-page":"1392375","DOI":"10.3389\/fonc.2024.1392375","article-title":"GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report","volume":"14","author":"Crowley","year":"2024","journal-title":"Front Oncol"},{"key":"2026043010445971300_ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026043010445971300_ref10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026043010445971300_ref11","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026043010445971300_ref12","doi-asserted-by":"publisher","first-page":"e70932","DOI":"10.1002\/cam4.70932","article-title":"The impact and safety of GLP-1 agents and breast cancer","volume":"14","author":"Parsons","year":"2025","journal-title":"Cancer Med"},{"key":"2026043010445971300_ref13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026043010445971300_ref14","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.diabet.2022.101366","article-title":"Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"48","author":"Li","year":"2022","journal-title":"Diabetes Metab"},{"key":"2026043010445971300_ref15","doi-asserted-by":"publisher","first-page":"C1822","DOI":"10.1152\/ajpcell.00245.2025","article-title":"GLP-1 receptor agonists in the context of cancer: the road ahead","volume":"328","author":"Miousse","year":"2025","journal-title":"Am J Physiol-Cell Physiol"},{"key":"2026043010445971300_ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a Nationwide analysis of 1.1 million patients","volume":"17","author":"Levy","year":"2024","journal-title":"Cancers."},{"key":"2026043010445971300_ref17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026043010445971300_ref18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026043010445971300_ref19","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026043010445971300_ref20","doi-asserted-by":"publisher","first-page":"e040919","DOI":"10.1101\/2025.01.02.25319923","article-title":"The role of GLP-1 receptor agonists in managing cancer therapy-related cardiac dysfunction","volume":"14","author":"Vignarajah","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026043010445971300_ref21","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026043010445971300_ref22","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026043010445971300_ref23","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci"},{"key":"2026043010445971300_ref24","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1064-P","article-title":"Identification of subpopulations exhibiting the greatest cardiovascular benefit from long-acting glucagon-like Peptide-1 receptor agonists\u2014a combined analysis of large cardiovascular outcome trials","volume":"67","author":"Kang","year":"2018","journal-title":"Diabetes."},{"key":"2026043010445971300_ref25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/15384101.2017.1334022","article-title":"Chemo brain: from discerning mechanisms to lifting the brain fog\u2014an aging connection","volume":"16","author":"Kovalchuk","year":"2017","journal-title":"Cell Cycle"},{"key":"2026043010445971300_ref26","doi-asserted-by":"publisher","first-page":"901559","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR Signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026043010445971300_ref27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026043010445971300_ref28","doi-asserted-by":"publisher","first-page":"e24140","DOI":"10.1200\/JCO.2024.42.16_suppl.e24140","article-title":"Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer","volume":"42","author":"Fischbach","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026043010445971300_ref29","doi-asserted-by":"publisher","first-page":"10607","DOI":"10.1200\/JCO.2024.42.16_suppl.10607","article-title":"Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026043010445971300_ref30","doi-asserted-by":"publisher","first-page":"e13063","DOI":"10.1200\/JCO.2024.42.16_suppl.e13063","article-title":"Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: a comparative analysis","volume":"42","author":"Urueta Portillo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026043010445971300_ref31","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4145444","article-title":"Abstract 4145444: GLP-1 receptor agonists and clinical events after Anthracycline-based chemotherapy: a propensity score-matched cohort study","volume":"150","author":"Felix","year":"2024","journal-title":"Circulation."},{"key":"2026043010445971300_ref32","doi-asserted-by":"publisher","first-page":"12026","DOI":"10.1200\/JCO.2024.42.16_suppl.12026","article-title":"The impact of glucagon-like peptide 1 agonists on anthracycline or human epidermal growth factor receptor 2 inhibitor-associated cardiotoxicity in patients with breast cancer and diabetes mellitus","volume":"42","author":"Chiang","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026043010445971300_ref33","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-735","article-title":"Abstract 735: the associations between the use of GLP-1 receptor agonists, cancer recurrence and all-cause mortality among cancer survivors","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res"},{"key":"2026043010445971300_ref34","doi-asserted-by":"publisher","first-page":"e2521887","DOI":"10.1001\/jamanetworkopen.2025.21887","article-title":"GLP-1 RA use and survival among older adults with cancer and type 2 diabetes","volume":"8","author":"Radwan","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026043010445971300_ref35","doi-asserted-by":"publisher","first-page":"1606088","DOI":"10.3389\/ijph.2023.1606088","article-title":"The role of cancer in the risk of cardiovascular and all-cause mortality: a Nationwide prospective cohort study","volume":"68","author":"Shen","year":"2023","journal-title":"Int J Public Health"},{"key":"2026043010445971300_ref36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11936-018-0645-8","article-title":"Cardiovascular risk in cancer survivors","volume":"20","author":"Agmon Nardi","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026043010445971300_ref37","first-page":"250","article-title":"Cardio-oncology: a focused review of Anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management","volume":"16","author":"Domercant","year":"2016","journal-title":"Ochsner J"},{"key":"2026043010445971300_ref38","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","article-title":"Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications","volume":"101","author":"Ren","year":"2021","journal-title":"Physiol Rev"},{"key":"2026043010445971300_ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-025-02471-3","article-title":"Chemo\u2212\/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum","author":"Suliman","journal-title":"Strahlenther Onkol"},{"key":"2026043010445971300_ref40","doi-asserted-by":"publisher","first-page":"971295","DOI":"10.3389\/fpain.2022.971295","article-title":"Cancer cachexia: pathophysiology and association with cancer-related pain","volume":"3","author":"Law","year":"2022","journal-title":"Front Pain Res"},{"key":"2026043010445971300_ref41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00394-022-02975-z","article-title":"Energy balance in cancer survivors at risk of weight gain: a review","volume":"62","author":"McNeil","year":"2023","journal-title":"Eur J Nutr"},{"key":"2026043010445971300_ref42","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","article-title":"Management of common clinical problems experienced by survivors of cancer","volume":"399","author":"Emery","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"2026043010445971300_ref43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1467-789X.2010.00805.x","article-title":"Weight gain in breast cancer survivors: prevalence, pattern and health consequences","volume":"12","author":"Vance","year":"2011","journal-title":"Obes Rev"},{"key":"2026043010445971300_ref44","doi-asserted-by":"publisher","first-page":"djv275","DOI":"10.1093\/jnci\/djv275","article-title":"Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis","volume":"107","author":"Playdon","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026043010445971300_ref45","doi-asserted-by":"publisher","first-page":"e2337780","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026043010445971300_ref46","doi-asserted-by":"publisher","first-page":"21145","DOI":"10.1038\/s41598-022-25043-2","article-title":"Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy","volume":"12","author":"Acevedo","year":"2022","journal-title":"Sci Rep"},{"key":"2026043010445971300_ref47","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/jnci\/djad113","article-title":"Obesity and prostate cancer screening, incidence, and mortality in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"115","author":"Hurwitz","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2026043010445971300_ref48","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"2026043010445971300_ref49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12032-024-02441-2","article-title":"Incidence of lymphedema related to various cancers","volume":"41","author":"Letellier","year":"2024","journal-title":"Med Oncol"},{"key":"2026043010445971300_ref50","doi-asserted-by":"publisher","DOI":"10.2458\/lymph.4649","article-title":"The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the INTERNATIONAL society of LYMPHOLOGY","volume":"53","author":"Document C","journal-title":"Lymphology."},{"key":"2026043010445971300_ref51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10549-006-9297-6","article-title":"Long-term Management of Breast Cancer-Related Lymphedema after intensive decongestive physiotherapy","volume":"101","author":"Vignes","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"2026043010445971300_ref52","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jvsv.2022.03.008","article-title":"A review of American insurance coverage and criteria for conservative management of lymphedema","volume":"10","author":"Finkelstein","year":"2022","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"2026043010445971300_ref53","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/cncr.33183","article-title":"A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (alliance)","volume":"127","author":"Paskett","year":"2021","journal-title":"Cancer."},{"key":"2026043010445971300_ref54","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk?","volume":"36 Suppl 2","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"2026043010445971300_ref55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like Peptide-1\u2013based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology."},{"key":"2026043010445971300_ref56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine."},{"key":"2026043010445971300_ref57","doi-asserted-by":"publisher","first-page":"107401","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026043010445971300_ref58","doi-asserted-by":"publisher","first-page":"102834","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2026043010445971300_ref59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an International multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid\u00ae."},{"key":"2026043010445971300_ref60","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA use and thyroid cancer risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"2026043010445971300_ref61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of hepatocellular carcinoma with glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"Shabil","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2026043010445971300_ref62","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026043010445971300_ref63","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11255-024-04266-4","article-title":"Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis","volume":"57","author":"Sharma","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026043010445971300_ref64","volume-title":"First-of-its-Kind Breast Cancer Research Study Explores the Impact of Weight Loss Drugs on Recurrence","year":"2024"},{"key":"2026043010445971300_ref65","volume-title":"OZEMPIC (Semaglutide) Injection, for Subcutaneous Use","year":"2025"},{"key":"2026043010445971300_ref66","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of dual-Labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026043010445971300_ref67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like Peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals."},{"key":"2026043010445971300_ref68","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Hamid","year":"2022","journal-title":"Adv Cancer Res"},{"key":"2026043010445971300_ref69","doi-asserted-by":"publisher","first-page":"2040622320970354","DOI":"10.1177\/2040622320970354","article-title":"Gastrointestinal side effects of cancer treatments","volume":"11","author":"O\u2019Reilly","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"2026043010445971300_ref70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide \u22121-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026043010445971300_ref71","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/jcsm.13510","article-title":"The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: a systematic literature review","volume":"15","author":"Dunne","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026043010445971300_ref72","volume-title":"Cancer Cachexia: After Years of No Advances, Progress Looks Possible","year":"2022"},{"key":"2026043010445971300_ref73","doi-asserted-by":"publisher","first-page":"112924","DOI":"10.1016\/j.diabres.2025.112924","article-title":"GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review","volume":"229","author":"Pantazopoulos","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026043010445971300_ref74","doi-asserted-by":"publisher","first-page":"e13677","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026043010445971300_ref75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2026043010445971300_ref76","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.clon.2020.05.015","article-title":"Optimising medications for patients with cancer and multimorbidity: the case for Deprescribing","volume":"32","author":"Turner","year":"2020","journal-title":"Clin Oncol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag044\/68195364\/qgag044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag044\/68195364\/qgag044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:45:04Z","timestamp":1777560304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article\/doi\/10.1093\/postmj\/qgag044\/8665749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgag044","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"qgag044"}}